Zacks Investment Research upgraded OpGen Inc (NASDAQ:OPGN) to Hold in a report released today.
- Updated: October 11, 2016
Yesterday OpGen Inc (NASDAQ:OPGN) traded 0.62% higher at $1.61. The company’s 50-day moving average is $1.66 and its 200-day moving average is $1.61. The last stock close price is down -0.28% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 315,757 shares of the stock were exchanged, down from an average trading volume of 757,263
Zacks Investment Research has upgraded OpGen Inc (NASDAQ:OPGN) to Hold in a report released on 10/12/2016.
See Chart Below
OpGen Inc has a 52 week low of $1.02 and a 52 week high of $4.65 The company’s market cap is currently $0.
About OpGen Inc (NASDAQ:OPGN)
OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company's high-resolution DNA tests are marketed under the Acuitas trade name.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.